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COST-EFFECTIVENESS ANALYSIS OF ARTHROSCOPIC SURGERY
COMPARED TO NON-OPERATIVE MANAGEMENT FOR
OSTEOARTHRITIS OF THE KNEE
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Purpose: Arthroscopic debridement and partial resection of degener-
ative joint tissues in patients with knee osteoarthritis (OA) is frequently
performed, yet its value is highly debated. The purpose of the present
analysis was to determine the cost-effectiveness of arthroscopic surgery
compared to non-operative treatment for knee OA.
Methods: The present data were collected as part of a previously
reported randomized controlled trial. Patients with knee OA were
randomly assigned to arthroscopic surgery combined with optimized
physical and medical therapy or to treatment with physical and medical
therapy alone, and were followed for two years. We used the WOMAC
total score and the quality-adjusted life year (QALY) at two years post-
operative as the effectiveness measures in our cost-effectiveness anal-
ysis. We recorded the total costs for each intervention, as well as all
health care resource use at each follow up appointment. All costs are
presented in 2012 Canadian dollars. We conducted a cost-effectiveness
analysis from a public health payer perspective and a societal per-
spective. We calculated the incremental cost-effectiveness ratio (ICER),
the incremental cost-utility ratio (ICUR), and estimated cost-effective-
ness using the net beneﬁt regression framework.
Results: A total of 169 patients were included in the cost-effectiveness
analysis (88 arthroscopy group, 81 non-operative group). Patients
allocated to the arthroscopy group received partial resection of
degenerative meniscal tears (81%) and/or debridement of degenerative
articular cartilage (97%). The ICER was $13,010 (CAN) (societal), or
$11,058 (CAN) (payer) for a clinically important improvement on the
WOMAC total score. The ICUR was $107,325 (CAN) (societal) or $91,230
(CAN) (payer) per QALY gained. The incremental net beneﬁt was neg-
ative for all willingness-to-pay values, from both the healthcare payer
and societal perspectives, suggesting that arthroscopic surgery is not
cost-effective compared to non-operative management.
Conclusions: The results of the present analysis suggest that arthro-
scopic debridement for the treatment of knee OA is not cost-effective
compared to non-operative management, in terms of disease-speciﬁc
quality of life and quality adjusted life years, from both a healthcare
payer and societal perspective.
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SUPPRESSION OF REDD1 IN OA CARTILAGE, A NOVEL MECHANISM
FOR DYSREGULATED MTOR ACTIVATION
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Purpose: Aging is a main risk factor for the development of osteo-
arthritis (OA) and the molecular mechanisms underlying the aging-
related changes in articular cartilage are beginning to be elucidated.
Using genome wide transcriptomic analysis, we identiﬁed the PI3K/Akt/
mTOR pathway as one of the most dysregulated pathways in OA carti-
lage, and REDD1, a regulator of cellular stress responses, as the most
suppressed gene in this pathway. The PI3K/Akt/mTOR signaling pathway
is a major driver of aging in model organisms and its role in OA patho-
genesis is emerging with abnormal mTOR activation becoming recog-
nized as an important dysfunction in OA chondrocytes. Therefore, the
present study analyzed REDD1 expression in normal and OA cartilage
and assessed REDD1 function in cultured human articular chondrocytes.
Methods: REDD1 expression was measured in articular cartilage
obtained from young healthy donors (38±13 years) or OA donors
undergoing knee replacement surgery (71±10 years) by qPCR and
immunohistochemistry. For in vitro studies, normal articular chon-
drocytes were treated with IGF-1, speciﬁc inhibitors of the PI3K/Akt/
mTOR and ERK pathways, in the presence or absence of REDD1 speciﬁc
siRNA. REDD1 expression, intracellular signaling pathway activation,
and autophagy weremeasured bywestern blot using antibodies against
REDD1, phospho-AKT, AKT, phospho-ERK, ERK, phospho-S6, S6, phos-
pho-4EBP and LC3, respectively.
Results: Human cartilage from normal knee joints expressed high levels
of REDD1 mRNA and protein. Immunohistochemistry showed predom-
inant REDD1 expression in the superﬁcial and upper-mid zones ascompared with the deep zone of the cartilage. REDD1 expression was
signiﬁcantly reduced in OA cartilage at both mRNA and protein levels. In
cultured chondrocytes, REDD1 protein expression was increased by
serum and IGF-1 treatment. IGF-1-induced REDD1 expression was
blocked by PI3K and mTOR inhibitors, but not by ERK inhibitors. REDD1
knockdown using siRNA resulted in increased S6 and 4EBP phosphor-
ylation, markers of increased mTOR activation. Finally, REDD1 knock-
downdecreased theLC3-II/GAPDHratio inhumanarticularchondrocytes.
Conclusions: The present study shows that REDD1 is highly expressed
in normal human articular cartilage and reduced in OA. Loss of REDD1
in human chondrocytes increases mTOR activity and decreases
autophagy activation. Collectively, these results suggest that REDD1 is
an important regulator of chondrocyte intracellular signaling andmTOR
inhibitor. Reduced REDD1 expression represents a novel mechanism for
the increased mTOR activation observed in OA.
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THE HARWELL AGEING SCREEN: A DISCOVERY PLATFORM FOR
GENES AND PATHWAYS ASSOCIATED WITH AGE-RELATED DISEASE
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Purpose: Diseases associated with ageing pose an increasing social and
ﬁnancial burden on society and represent an imperative for research in
the biomedical sciences. Despite the complications of genetic back-
ground in human populations and the confounds of environment, there
have been considerable advances, particularly through Genome-wide
association studies (GWAS) in identifying loci involved in diseases of
ageing. Nevertheless, this is only a ﬁrst step towards a more funda-
mental understanding of the genetic pathways involved. Animal models
are required both to test our understanding of these pathways, as well
as to provide the tools for developing and assessing therapeutics. We
are undertaking the ﬁrst large-scale project to investigate the inter-
action between genetic variation and the pleiotropic effects of ageing.
Methods: We are employing mutagenesis and phenotyping to speciﬁ-
cally generatenewmousemodels of late onset or age-related disease. The
emphasis is on the exploration of the phenotype space in ageing mouse
mutant populations providing us with the opportunity to: identify genes
and pathways involved in age related disease, scrutinise thesemodels for
biomarkers of age related disease, and provide better platforms for pre-
clinical assessmentof new therapies for suchdiseases. Pedigrees are aged
to 18 months and undergo comprehensive phenotyping across a wide
range of disease areas at several time points throughout the life of the
mice. Mutations are mapped initially by a dense SNP panel and then
individual mutations identiﬁed by whole genome sequencing.
Results: To date we have identiﬁed lines with age-related hearing loss,
cardiovascular disease, retinal degeneration, neurodegeneration, obe-
sity, and bone disease which are being mapped and characterised in
detail. We have identiﬁed two lines with late onset osteoarthritis. MP-
107 was identiﬁed as having mild skeletal abnormalities, particularly a
curved and wider ischium at 4 months of age. Upon ageing affected
mice developed increased boney deposits at the joints, identiﬁed by X
ray, and upon histopathological analysis showed osteophyte formation
and cartilage erosion. This line was mapped as a dominant phenotype
and localised to chromosome 11. An existing line (TM-44) also displayed
similar ischium abnormalities and also maps to chromosome 11. Whole
genome sequencing of MP-107 identiﬁed a non-synonymous change
(T304M) in ST6galnac2 (ST6(alpha-N-acetyl-neuraminyl-2,3-beta-gal-
actosyl-1,3)-N-acetylgalactosaminide alpha-2, 6-sialyltransferase 2). A
detailed time course of the pathogenesis of disease and functional
pathways is now underway in these lines to conﬁrm ST6galnac2T304M
as the causative mutation. In the pedigree MPC-227 mice were identi-
ﬁed with severe joint deterioration by 15 months of age. The causative
mutation was mapped to a missense mutation (A1946V) in aggrecan
(Acan). In addition to the joint deterioration these mice exhibited
quantitative and qualitative differences in brown and white adipose
tissue with ageing, resulting in obesity in ageing mutant mice. Acan
mutations in humans have been associated with an increased incidence
of osteoarthritis in humans and this mutant line will allow the inves-
tigation of pathogenic pathways associated with Acan abnormalities.
We are also investigated the role of Acan in adipose tissue.
Conclusions: The age challenged mice are an important resource for
many research groups, identifying novel genes and pathways resulting
